Pharmaceutical Strategy Could Save European ATMP Development
Better RWE Infrastructure And Pricing Models Also Key To European ATMP Sector
Executive Summary
The European Commission’s Pharmaceutical Strategy should end regulatory “carve outs” like the hospital exemptions, and innovate pricing and reimbursement structures, says the Alliance for Regenerative Medicines.
You may also be interested in...
Industry Bodies Urge GMO Exemption For Advanced Therapies In EU
ATMPs should be treated like COVID-19 products when it comes to the EU rules on genetically modified organisms, say ARM, EFPIA and EuropaBio.
EU Eases GMO Rules To Speed Trials Of COVID-19 Vaccines
The need to accelerate clinical trials of products for treating and preventing coronavirus has led the EU authorities to propose a more streamlined process for allowing the release of GMO-containing investigational medicinal products into the environment.
EU Pharmaceutical Strategy Roadmap Seen As Weak On Innovation
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.